Fundraising FoxPandion Therapeutics
Unicorn exit · $1.9Bacquired by MerckCambridge, US · Founded 2016 · Delaware corporation · 7 known investors
Find your way into Pandion Therapeutics
Sign up to see every warm intro you have to Pandion Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Pandion Therapeutics team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by Merck February 2021 · $1.9B ($60 per share cash, ~$1.85 billion total equity value) · source ↗
Developing biologic therapies for autoimmune disorders; acquired by Merck for $1.85B in 2021.
Founders & leadership
Pandion Therapeutics was founded in 2016 by Jo Viney.
Board
Investors · 7
How we know: Access Biotechnology's portfolio page · Not right? Tell us
How we know: Mission Biocapital's portfolio page · Not right? Tell us
How we know: SR One Capital Management's portfolio page · Not right? Tell us
How we know: a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$61.6M disclosed across 2 rounds · 2018–2020
▶$40MraisedApr 2020 · 23 investors · BiotechnologyRule 506(b)
- Christopher FuglesangDirector
- Carlo RizzutoDirector
- Nancy StaglianoDirector
- Donald FrailDirector
- Mitchell MutzDirector
- Rahul KakkarExecutive Officer, Director
- Daniel BeckerDirector
- Alan L. CraneDirector
- Vikas GoyalExecutive Officer
- Jill CarrollDirector
- Jo VineyExecutive Officer
- Offering amount
- $80M
- Amount sold
- $40M
- First sale
- Mar 2020
- Incorporated
- Limited Liability Company, Delaware, 2018
- Federal exemptions
- 06b
▶$21.6MraisedJan 2018 · 5 investors · BiotechnologyRule 506(b)
- Vikas GoyalDirector
- Jo VineyExecutive Officer
- Mitchell MutzDirector
- Carlo RizzutoDirector
- Alan CraneDirector
- Anthony CoyleExecutive Officer, Director
- Offering amount
- $57.6M
- Amount sold
- $21.6M
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Pandion Therapeutics went on to found or lead other companies.
Frequently asked questions
- What does Pandion Therapeutics do?
- Developing biologic therapies for autoimmune disorders; acquired by Merck for $1.85B in 2021.
- Who founded Pandion Therapeutics?
- Pandion Therapeutics was founded by Jo Viney in 2016.
- Who are Pandion Therapeutics's investors?
- Pandion Therapeutics's investors include Access Biotechnology, JDRF T1D Fund, Mission Biocapital, RA Capital, SR One Capital Management, Polaris Partners, Versant Ventures.
- How much funding has Pandion Therapeutics raised?
- Pandion Therapeutics has disclosed $61.6M raised across 2 rounds.
- Who acquired Pandion Therapeutics?
- Pandion Therapeutics was acquired by Merck.
- Where is Pandion Therapeutics headquartered?
- Pandion Therapeutics is headquartered in Cambridge, US.